Skip to main content

Table 5 Antimicrobial susceptibility of Gram-negative isolates

From: Epidemiology of patients with central nervous system infections, mainly neurosurgical patients: a retrospective study from 2012 to 2019 in a teaching hospital in China

  Acinetobacter baumannii (N = 6) Escherichia coli (N = 6) Klebsiella pneumoniae (N = 3) Klebsiella oxytoca (N = 2)
n S I R n S I R n S I R n S I R
Piperacillin 6    6 (100%)          
Piperacillin Tazobactam 6    6 (100%) 6 5 (83.3%) 1 (16.7%)   3    3 (100%) 2 1 (50%)   1 (50%)
Cefazolin     6 1 (16.7)   5 (83.3%) 3    3 (100%) 2    2 (100%)
Cefuroxime     6 1 (16.7%)   5 (83.3%) 3    3 (100%) 2 1 (50%)   1 (50%)
Ceftriaxone     5 2 (40%)   3 (60%) 3    3 (100%) 2    2 (100%)
Ceftazidime 6 1 (16.7%)   5 (83.3%) 6 4 (66.7%)   2 (33.3%) 3    3 (100%) 2 1 (50%)   1 (50%)
Cefepime 6    6 (100%) 6 3 (50%)   3 (50%) 3    3 (100%) 2   1 (50%) 1 (50%)
Cefoxitin     6 5 (83.3%) 1 (16.7%)   3    3 (100%) 2 1 (50%)   1 (50%)
Cefoperazone Sulbactam 6    6 (100%) 6 4 (66.7%) 1 (16.7%) 1 (16.7%) 3    3 (100%) 2   1 (50%) 1 (50%)
Aztreonam     5 1 (20%) 1 (20%) 3 (60%) 2    2 (100%) 1    1 (100%)
Amikacin 6 1 (16.7%)   5 (83.3%) 6 6 (100%)    3 1 (33.3%)   2 (66.7%) 2 1 (50%)   1 (50%)
Tobramycin 6 1 (16.7%)   5 (83.3%)          
Ciprofloxacin 6 1 (16.7%)   5 (83.3%) 5    5 (100%) 2    2 (100%) 1   1 (100%)  
Levofloxacin 6 1 (16.7%)   5 (83.3%) 6 1 (16.7%) 1 (16.7%) 4 (66.7%) 3    3 (100%) 2   1 (50%) 1 (50%)
Compound Sulfamethoxazole 6   2 (33.3%) 4 (66.7%)          
Meropenem 6    6 (100%) 6 6 (100%)    3    3 (100%) 2 1 (50%)   1 (50%)
Imipenem 6    6 (100%) 6 6 (100%)    3    3 (100%) 2 1 (50%)   1 (50%)
Minocycline 6 5 (83.3%)   1 (16.7%)          
Tigecycline 2 2 (100%)       2 2 (100%)      
  1. S sensitive, I intermediary, R resistant, (–) not done